Complaint
| item | details |
| Product name | sermaglutide |
| use | Obesity and weight loss |
| shape | Lyophilized powder |
| rank | Pharmaceutical grade |
| Packaging container | Glass freeze-dried bottle |
| inventory | Spot goods |
Product description
| Product name | Sermaglutide |
| CAS number | 910463-68-2 |
| Molecular formula | C187H291N45O59 |
| Molecular weight | 4113.57754 |
| Appearance | White powder |
| Purity | 99.0% |
| Function | Semaglutide can reduces hunger, food craving and body fat. |
| Discribe | Semaglutide is a new generation GLP-1 (glucagon-like peptide-1) analogues. Semaglutide is a long-acting dosage form based on the basic structure of liraglutide, which is more effective in the treatment of type 2 diabetes mellitus. Compared with lilarlutide, somalutide has a longer aliphobic chain and an increased hydrophobicity, but somalutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced.PEG modification can not only tightly bind to albumin, cover up the DPP-4 enzymatic hydrolysis site, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation. Semaglutide (USAN; trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozempic. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016. FDA approval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour. It can be used as both injection-type or oral-type drug. Researchers at the University of Leeds reported in 2017 that it can also be used for the treatment of obesity. It reduces hunger, food craving and body fat. |
